在刚刚过去的2025年的世界肺癌大会(WCLC)年会上,来自中国药企百利天恒的EGFR/HER3双抗ADC(BL-B01D1)以其石破天惊的疗效数据,在全球肿瘤学界掀起了一场风暴。这一事件标志着由双特异性抗体(BsAb)及其偶联药物(BsADC)引领的新纪元,已经全面来临。双特异性抗体(BsAb)通过其独特的结构,能够同时与两种不同的靶点结合,实现双重作用机制。相较于传统的单克隆抗体(单抗),双抗...
Source Link在刚刚过去的2025年的世界肺癌大会(WCLC)年会上,来自中国药企百利天恒的EGFR/HER3双抗ADC(BL-B01D1)以其石破天惊的疗效数据,在全球肿瘤学界掀起了一场风暴。这一事件标志着由双特异性抗体(BsAb)及其偶联药物(BsADC)引领的新纪元,已经全面来临。双特异性抗体(BsAb)通过其独特的结构,能够同时与两种不同的靶点结合,实现双重作用机制。相较于传统的单克隆抗体(单抗),双抗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.